US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eaton Vance National Municipal Opportunities Trust

16.74

-0.0350-0.21%

Post-market: 17.390.6499+3.88%18:12 EDT

Volume:27.01K

Turnover:452.85K

Market Cap:261.56M

PE:-4.32

High:16.94

Open:16.87

Low:16.62

Close:16.78

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds

Press Release: Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EOT"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EOT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EOT\",,,,,undefined,":{"symbol":"EOT","market":"US","secType":"STK","nameCN":"Eaton Vance National Municipal Opportunities Trust","latestPrice":16.74,"timestamp":1743710400000,"preClose":16.775,"halted":0,"volume":27012,"hourTrading":{"tag":"盘后","latestPrice":17.3899,"preClose":16.74,"latestTime":"18:12 EDT","volume":100,"amount":1738.99,"timestamp":1743718359339},"delay":0,"floatShares":0,"shares":15624921,"eps":-3.87454,"marketStatus":"Post-Market Trading","change":-0.035,"latestTime":"04-03 19:41:08 EDT","open":16.87,"high":16.94,"low":16.62,"amount":452845.45623600006,"amplitude":0.019076,"askPrice":17.54,"askSize":4900,"bidPrice":15.42,"bidSize":4900,"shortable":3,"etf":0,"ttmEps":-3.87454,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743724800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":16.775,"postHourTrading":{"tag":"盘后","latestPrice":17.3899,"preClose":16.74,"latestTime":"18:12 EDT","volume":100,"amount":1738.99,"timestamp":1743718359339},"volumeRatio":0.933225},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EOT\",,,,,undefined,":{"symbol":"EOT","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.933225,"shares":15624921,"dividePrice":0.8196,"high":16.94,"amplitude":0.019076,"preClose":16.775,"low":16.62,"week52Low":16.18,"pbRate":"--","week52High":18.47,"institutionHeld":0,"latestPrice":16.74,"eps":-3.87454,"divideRate":0.048961,"volume":27012,"delay":0,"ttmEps":-3.87454,"open":16.87,"prevYearClose":16.46,"prevWeekClose":16.71,"prevMonthClose":16.65,"prevQuarterClose":16.65,"fiveDayClose":16.67,"twentyDayClose":16.964,"sixtyDayClose":16.62},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EOT\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EOT\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524126434","title":"Press Release: Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds","url":"https://stock-news.laohu8.com/highlight/detail?id=2524126434","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524126434?lang=en_us&edition=fundamental","pubTime":"2025-04-02 04:00","pubTimestamp":1743537600,"startTime":"0","endTime":"0","summary":"The following Eaton Vance closed-end funds  announced distributions today as detailed below.Declaration -- 4/1/2025 Ex-Date -- 4/11/2025 Record -- 4/11/2025 Payable --","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ETY","EFR","LU2028103732.USD","LU1732800096.USD","LU0106261372.USD","US12M.BOND","LU0158827948.USD","EOI","US7Y.BOND","LU0267386448.USD","ENX","CEV","US30Y.BOND","EVN","BK4585","EVG","US5Y.BOND","IE00BKVL7J92.USD","EVM","ETB","EVT","ETW","US10Y.BOND","LU0225283273.USD","EFT","ETJ","LU0106831901.USD","US2Y.BOND","EOS","EOT","LU2089283258.USD","ETV","EVF","ETG","EVV","LU1074936037.SGD","EXG","ETO","US3Y.BOND","IE00BZ1G4Q59.USD","ETX","US6M.BOND","EIM","BK4534"],"gpt_icon":0},{"id":"2521402813","title":"Press Release: Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521402813","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521402813?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:10","pubTimestamp":1742555400,"startTime":"0","endTime":"0","summary":"Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure. Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations. 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL . Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028. \"The critical milestones we achieved in 2024 have strengthened our HBV portfolio of multiple mechanisms of action at both the clinical and strategic level,\" stated Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio. \"Data from multiple ongoing combination studies with our highly differentiated HBV assets continue to show that our multi-modal approach has the potential to produce higher functional cure rates across broader HBV","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4018","BK1161","BK4585","BK4588","CHD","BK1587","LU1430594728.SGD","BK4504","LU1585245621.USD","02137","EOT","BK1574"],"gpt_icon":0},{"id":"2483091990","title":"Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483091990","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483091990?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:00","pubTimestamp":1731499200,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024.Highlights of the third quarter ended September 30, 2024, or in some cases shortly thereafter, include:. Also in July 2024, and very timely given our late-stage development progress, the USPTO  granted Acurx a new patent for ibezapolstat which specifically encompasses the \"treatment of C. difficile Infection while reducing recurrence of infection and improving the health of the gut microbiome\". This patent expires in June 2042 and we believe will provide an important downstream competitive advantage.Additionally in September 2024, we announced that selected ACX-375 DNA pol IIIC analogues demonstrated in vitro activity against B. anthracis , which is a Bioterrorism Category A pathoge","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jZTlKjgzq39AhhwD0Ujy9Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/0acee424d62555a0f2cf4b64e1517f23","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jZTlKjgzq39AhhwD0Ujy9Q--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/0acee424d62555a0f2cf4b64e1517f23"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acurx-pharmaceuticals-inc-reports-third-120000114.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-pharmaceuticals-inc-reports-third-120000114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4139","EOT","ACXP","BK4539","VRE","BK4563","BK4194","GAIN"],"gpt_icon":1},{"id":"2477885503","title":"Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2477885503","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477885503?lang=en_us&edition=fundamental","pubTime":"2024-10-21 19:00","pubTimestamp":1729508400,"startTime":"0","endTime":"0","summary":"The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection . Ibezapolstat treatment of patients with CDI is associated with the restoration of beneficial bacterial classes in the gut. Preparing to submit requests for regulatory guidance to initiate clinical trials in the European Union to be followed by the United Kingdom, Japan and Canada. Ibezapolstat has previously received FDA QIDP and Fast-Track Designation from FDA. According to Dr. Garey: \"These exciting results demonstrate two properties of ibezapolstat which may contribute to the anti-recurrence effect. First, the preservation and restoration of beneficial bacterial classes in the gut provide resistance to recolonization by C. difficile. Second, these data, presented for the first time, indicate that these beneficial bacteria known to metabolize primary to secondary bile acids persist in ibezapolstat-treated patie","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/o4yTSZlWqQ5nqpO6DqQ9eg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/29f82a8025a230f34a2427fcc2827bf8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/o4yTSZlWqQ5nqpO6DqQ9eg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/29f82a8025a230f34a2427fcc2827bf8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acurx-announces-bile-acid-microbiome-110000859.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acurx-announces-bile-acid-microbiome-110000859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EOT","BK4135","BK4539","BK4181","VRE","BK4194","BK4139","BK4563","IDSA","ECC","ACXP","BK4218","GAIN","PK"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EOT\",params:#limit:5,,,undefined,":[{"date":"2025-04-15","symbol":"EOT","amount":0.0683,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-15","defaultRemindTime":1744723800000,"name":"Eaton Vance National Municipal O","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-15","currency":"USD","dateTimestamp":1744689600000,"payDate":"2025-04-30"},{"date":"2025-03-14","symbol":"EOT","amount":0.0683,"announcedDate":"2025-03-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-14","defaultRemindTime":1741959000000,"name":"Eaton Vance National Municipal O","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-14","currency":"USD","dateTimestamp":1741924800000,"payDate":"2025-03-31"},{"date":"2025-02-14","symbol":"EOT","amount":0.0683,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-14","defaultRemindTime":1739543400000,"name":"Eaton Vance National Municipal O","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-28","payableDate":"2025-02-14","currency":"USD","dateTimestamp":1739509200000,"payDate":"2025-02-28"},{"date":"2025-01-15","symbol":"EOT","amount":0.0683,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-15","defaultRemindTime":1736951400000,"name":"Eaton Vance National Municipal O","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-31","payableDate":"2025-01-15","currency":"USD","dateTimestamp":1736917200000,"payDate":"2025-01-31"},{"date":"2024-12-23","symbol":"EOT","amount":0.0683,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Eaton Vance National Municipal O","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EOT\",market:\"US\",,,undefined,":[{"executeDate":"2015-04-21","recordDate":"2015-04-23","paymentDate":"2015-04-30","value":0.085834,"currency":"USD"},{"executeDate":"2015-05-20","recordDate":"2015-05-22","paymentDate":"2015-05-29","value":0.085834,"currency":"USD"},{"executeDate":"2015-06-19","recordDate":"2015-06-23","paymentDate":"2015-06-30","value":0.085834,"currency":"USD"},{"executeDate":"2015-07-22","recordDate":"2015-07-24","paymentDate":"2015-07-31","value":0.085834,"currency":"USD"},{"executeDate":"2015-08-20","recordDate":"2015-08-24","paymentDate":"2015-08-31","value":0.085834,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EOT\",market:\"US\",delay:false,,,undefined,":{}}}